SynthesisFrontiers in oncology2026
Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligometastatic non-small cell lung cancer (NSCLC) represents a potentially modifiable stage of metastatic disease, however, the survival benefit of local consolidative therapy (LCT) in patients without actionable driver mutations remains uncertain in the era of immunotherapy. To address this clinically relevant controversy, we performed a systematic review and meta-analysis evaluating the efficacy and safety of adding LCT to systemic therapy in driver-negative oligometastatic NSCLC. A comprehensive search of PubMed, Embase, and the Cochrane Library through December 2025 identified 13 eligible studies including 1,698 patients. Pooled analyses demonstrated that the addition of LCT was significantly associated with improved overall survival (HR 0.45, 95% CI 0.36-0.56) and progression-free survival (HR 0.53, 95% CI 0.46-0.61) compared with systemic therapy alone. Notably, cumulative meta-analysis showed that the survival advantage remained stable as evidence accrued over time, underscoring the consistency of the treatment effect. LCT was also associated with a higher objective response rate (RR 1.47, 95% CI 1.12-1.93) without a significant increase in treatment-related adverse events (RR 1.31, 95% CI 0.93-1.84). Importantly, subgroup analyses demonstrated that the survival benefit persisted in studies incorporating immunotherapy-based regimens, suggesting that LCT retains clinical value even within contemporary systemic treatment paradigms. Sensitivity analyses confirmed the robustness of these findings, and no significant publication bias was detected. Collectively, these results indicate that integrating LCT into systemic therapy is associated with meaningful survival gains in driver-negative oligometastatic NSCLC without added toxicity, supporting a risk-adapted, multidisciplinary treatment strategy in the modern immunotherapy era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.